Percutaneous biopsy for the diagnosis, risk stratification, and molecular profiling of neuroblastoma: A single‐center retrospective study
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.30887 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Sean Schoeman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Nitrobenzenes. Die Arbeit nennt 24 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Purpose
To determine whether percutaneous core needle biopsy (PCNB) is adequate for the diagnosis and full molecular characterization of newly diagnosed neuroblastoma. Materials and methods Patients with newly diagnosed neuroblastoma who underwent PCNB in interventional radiology at a single center over a 5‐year period were included. Pre‐procedure imaging and procedure details were reviewed. Rates of diagnostic success and sufficiency for International Neuroblastoma Pathology Classification (INPC), risk stratification, and evaluation of genomic markers utilized in the Children's Oncology Group risk stratification, and status of the anaplastic lymphoma kinase ( ALK) gene were assessed.
Results
Thirty‐five patients (13 females, median age 2.4 years [interquartile range, IQR: 0.9–4.4] and median weight 12.4 kg [IQR: 9.6–18]) were included. Most had International Neuroblastoma Risk Group Stage M disease ( n = 22, 63%). Median longest axis of tumor target was 8.8 cm [IQR: 6.1–12]. A 16‐gauge biopsy instrument was most often used ( n = 20, 57%), with a median of 20 cores [IQR: 13–23] obtained. Twenty‐five specimens were assessed for adequacy, and 14 procedures utilized contrast‐enhanced ultrasound guidance. There were two post‐procedure bleeds (5.7%). Thirty‐four of 35 procedures (97%) were sufficient for histopathologic diagnosis and risk stratification, 94% ( n = 32) were sufficient for INPC, and 85% ( n = 29) were sufficient for complete molecular characterization, including ALK testing. Biologic information was otherwise obtained from bone marrow (4/34, 12%) or surgery (1/34, 2.9%). The number of cores did not differ between patients with sufficient versus insufficient biopsies.
Conclusion
In this study, obtaining multiple cores with PCNB resulted in a high rate of diagnosis and successful molecular profiling for neuroblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, USA.
- The Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Oncology, Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, USA.
- Division of General, Thoracic and Fetal Surgery, Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, USA.
- Division of Anatomical Pathology, Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, USA.
ORCID-Profile: Sean Schoeman, Rochelle Bagatell, John Maris
Förderung
- NCI NIH HHS
Zitieren
APA
Schoeman, S., Bagatell, R., Cahill, A. M., Maris, J., Mattei, P., Mosse, Y., Pogoriler, J., Srinivasan, A., & Acord, M. (2024). Percutaneous biopsy for the diagnosis, risk stratification, and molecular profiling of neuroblastoma: A single‐center retrospective study. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30887
Vancouver
Schoeman S, Bagatell R, Cahill AM, Maris J, Mattei P, Mosse Y, et al. Percutaneous biopsy for the diagnosis, risk stratification, and molecular profiling of neuroblastoma: A single‐center retrospective study. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30887
BibTeX
@article{Schoeman2024,
author = {Schoeman, Sean and Bagatell, Rochelle and Cahill, Anne Marie and Maris, John and Mattei, Peter and Mosse, Yael and Pogoriler, Jennifer and Srinivasan, Abhay and Acord, Michael},
title = {Percutaneous biopsy for the diagnosis, risk stratification, and molecular profiling of neuroblastoma: A single‐center retrospective study},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.30887}
}
EUVIMED